(19)
(11) EP 2 510 925 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.10.2016 Bulletin 2016/41

(45) Mention of the grant of the patent:
20.07.2016 Bulletin 2016/29

(21) Application number: 12001852.8

(22) Date of filing: 15.02.2007
(51) International Patent Classification (IPC): 
A61K 31/12(2006.01)
C07D 231/40(2006.01)
 C07C 233/60(2006.01)

(54)

Small-Molecule modulators of TRP-P8 activity

Kleinmolekulare Modulatoren der TRP-P8-Aktivität

Modulateurs à petites molécules de l'activité de TRP-P8

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK RS

(30) Priority: 15.02.2006 US 773435 P

(43) Date of publication of application:
17.10.2012 Bulletin 2012/42

(62) Application number of the earlier application in accordance with Art. 76 EPC:
07750861.2 / 1986622

(73) Proprietor: Dendreon Pharmaceuticals, Inc.
Bridgewater, NJ 08807 (US)

(72) Inventors:
  • Moreno, Ofir
    Seattle, Washington 98136 (US)
  • Natarajan, Sateesh
    Bellevue, Washington 98005 (US)
  • Duncan, David F.
    San Diego, California 92129 (US)

(74) Representative: Müller, Christian Stefan Gerd et al
ZSP Patentanwälte PartG mbB Radlkoferstrasse 2
81373 München
81373 München (DE)


(56) References cited: : 
WO-A2-2005/020897
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).